More on RYTM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $88.38 |
|
|||
| Open | $93.75 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $98.37 | ||||
| Day Low | $93.00 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 564,820 | ||||
- Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Post Release of Setmelanotide Data
- Rhythm Pharmaceuticals (RYTM) PT Raised to $155 at Wells Fargo
- Rhythm Pharmaceuticals reports positive Phase 2 data for PWS treatment
- Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
- Rhythm Pharmaceuticals schedules call on Prader-Willi syndrome trial data
- Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
- Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens
- Form DEFA14A RHYTHM PHARMACEUTICALS,
- Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
- Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
Entities mentioned with RYTM
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- Needham & Company | View Related Stories »
- Show More...
